The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Walnuts are packed with nutrients and promise benefits, including a lower risk of cardiovascular disease and strokes, and ...

While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...

To celebrate the Chinese Lunar New Year, KHON2 welcomed the Asian Lion Dance Team to the station to usher in good luck for ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...